Yes the P/E has increased but so has the company's R&D investment. This will impact the earnings part for now but is an investment in the future. Any successful innovation could see earnings explode bringing the P/E down, the market is always forward looking and will be factoring this into the share price.
DYOR
Blood supply shortage in the US, page-40
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.56 |
Change
-0.960(0.31%) |
Mkt cap ! $149.1B | |||
| Open | High | Low | Value | Volume |
| $309.28 | $309.39 | $307.78 | $13.91M | 45.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 51 | $308.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.57 | 9 | 3 |
View Market Depth
| Last trade - 10.52am 26/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |